Zai Lab Announces The New England Journal of Medicine Public

Phase 1/2 TRIDENT-1 study data demonstrate repotrectinib’s clinically meaningful response rates and durable clinical activity in patients with ROS1-positive non-small cell lung cancer


Data show...

Related Keywords

United States , Hong Kong , Taiwan , Macau , China , Chinese , Rafaelg Amado , , Zai Lab Limited , Drug Administration , National Medical Products Administration , Global Oncology Research , Exchange Commission , Zai Lab Forward , Bristol Myers Squibb Company , Zai Lab , Bristol Myers Squibb , New England Journal , Point Therapeutics , Turning Point Therapeutics , Greater China , Drug Evaluation , New Drug Application , Breakthrough Therapy Designations , Private Securities Litigation Reform Act , Thoracic Cancer January , Markets ,